COPENHAGEN, Denmark — September 14, 2026
Evaxion A/S announced that it has begun applying its proprietary AI-Immunology™ platform to autoimmune diseases, expanding the company’s therapeutic focus beyond its existing cancer and infectious-disease programs. Evaxion is conducting experimental testing of two novel AI-Immunology-based treatment concepts designed to potentially address underlying disease biology rather than primarily managing symptoms. The company believes the platform’s ability to identify highly specific immune targets could support development of treatments with potentially improved efficacy and fewer side effects compared with existing approaches. The expansion represents another strategic milestone for Evaxion in 2026 and creates potential opportunities for partnerships across different stages of autoimmune drug development. Initial experimental findings are expected to be presented at the Protein & Antibody Engineering Summit (PEGS) Europe in Lisbon on November 18, 2026.
Two AI-Based Therapeutic Concepts Enter Experimental Testing
Evaxion is evaluating a tolerogenic vaccine concept and an autoantibody binder concept as its initial approaches to autoimmune disease. The tolerogenic vaccine strategy is designed to use selected T-cell epitopes together with immune modulators to direct the immune system toward tolerance. Evaxion said AI-Immunology has capabilities for identifying and prioritizing potentially relevant epitopes, which could support the design of disease-specific immune interventions. The second concept focuses on autoantibodies, which can act as pathogenic drivers in multiple autoimmune diseases by binding to normal tissues and disrupting physiological functions. The company’s proposed autoantibody binder uses an antigen construct intended to capture these disease-associated autoantibodies, with the objective of removing them from circulation and potentially reducing their pathological effects. Both concepts remain at the experimental stage.
Disease Modification Drives Autoimmune Strategy
Evaxion’s autoimmune strategy is focused on potential disease modification rather than treating symptoms alone. Many autoimmune disorders require long-term treatment aimed at controlling excessive immune activity, while approaches capable of directly addressing disease-driving mechanisms remain an area of significant development interest. Evaxion believes its AI-Immunology platform could help identify highly specific immune targets and design therapeutic concepts around the underlying biology of individual diseases. The company is particularly evaluating how immune tolerance and selective removal of pathogenic autoantibodies could provide alternative approaches to current therapies. However, the two programs are still undergoing experimental testing, and their potential efficacy, safety and applicability across specific autoimmune diseases remain to be established. Data from the ongoing work will provide an initial assessment of the concepts and their potential for further development.
Advertisement
Evaxion Expands TechBio Partnership Potential
The move into autoimmune diseases broadens Evaxion’s AI-driven drug discovery strategy and could create new partnership opportunities across the pharmaceutical development lifecycle. AI-Immunology™ is designed to support target discovery, drug design and development by using artificial intelligence to decode aspects of the human immune system. The company currently applies the platform across cancer and infectious diseases, with a pipeline that includes personalized and off-the-shelf cancer vaccine candidates as well as prophylactic vaccine programs. The autoimmune expansion adds two new therapeutic concepts to that broader platform strategy while testing whether AI-enabled immune targeting can generate differentiated approaches to chronic inflammatory disease. With experimental validation now underway and initial data planned for PEGS Europe in November, Evaxion is positioning AI-Immunology as a broader technology platform capable of generating potential therapies across multiple immune-mediated diseases.
Source:Evaxion, press release
